Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Jenscare Scientific Co. Ltd. Class H ( (HK:9877) ) just unveiled an announcement.
Jenscare Scientific Co., Ltd. announced the follow-up results of its LuX-Valve Plus TRINITY study and JensClip clinical study at EuroPCR 2025, highlighting promising safety and performance outcomes. The LuX-Valve Plus TRINITY study, involving 161 patients across 20 centers, demonstrated a 97% device success rate and significant improvements in patients’ cardiac function and quality of life. The JensClip study also reported favorable one-year follow-up results, reinforcing the company’s position in the transcatheter heart valve market and potentially impacting stakeholders positively by showcasing the efficacy and safety of its products.
More about Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. is a company based in the People’s Republic of China, specializing in medical devices with a focus on transcatheter heart valve technologies. The company is engaged in developing innovative solutions for patients with severe heart valve diseases, particularly those at high surgical risk.
Average Trading Volume: 309,962
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.35B
For a thorough assessment of 9877 stock, go to TipRanks’ Stock Analysis page.